Placental Stem Cell Therapy for Neurological Disorders Market Size (2024 – 2030)

The Placental Stem Cell Therapy for Neurological Disorders Market was valued at USD 464.96 Million and is projected to reach a market size of USD 1,806.95 Million by the end of 2030. Over the forecast period of 2024-2030, the market is projected to grow at a CAGR of 21.4%. 

Placental stem cells emerge from the placental blood and other bodily fluids of newborn infants. Plentiful perinatal stem cells are present within both placental blood and tissues. Cord blood stem cells and umbilical cord tissues constitute additional integral components of the placenta. Stem cell therapy stands acclaimed for ushering significant and innovative advancements in cancer management and healthcare. Notably, conditions such as cancer, vascular disorders, and neurological disorders find effective therapeutic solutions within these offerings. Stem cell therapy has recently emerged as a promising contender in the realm of gene therapy, offering potential for tissue repair and regeneration. Moreover, the industry is increasingly recognizing the medicinal potential of stem cells for disease and disorder management. The human placenta demonstrates positive impacts on the immune system, while therapeutic applications of placental components, including amniotic membranes, contribute to wound healing, burn treatment, and oral cavity restoration, fostering the expansion of this market. Although extensive research has largely mitigated the risks and challenges linked to the derivation and cultivation of Placental Stem Cells (PSCs), ethical considerations remain, with the development of induced pluripotent stem cells serving as a means to address these concerns. The increasing volume of experimental scientific investigations that focus on the therapeutic efficacy of placental stem cells for neurological disorder treatment, alongside the establishment of stem cell line banking, plays a pivotal role in propelling the growth of the placental stem cell therapy industry.

Key Market Insights:

In the pursuit of broadening the clinical uses of placental stem cell therapies, players in the field are actively embracing various technologies and methodologies. Their focus lies on maintaining a steady standard of stem cell quality, prompting a significant emphasis on advancements in biobanking technologies. This has led to extensive exploration and study of placental stem cell therapies' characteristics.

Allogeneic human amniotic epithelial cells (hAECs) are demonstrating promise in addressing conditions like leukemia and bronchopulmonary dysplasia (BPD) across multiple stages of clinical trials. The increasing prevalence of allogeneic stem cell transplantation procedures in industrialized countries has positively impacted the sales outlook within the placental stem cell therapy market.

Ongoing developments in cell-based treatments have increased the industry's interest in utilizing placental stem cell therapy for a range of illnesses. This expansion is propelling the potential for increased sales within the placental stem cell therapy market. Particularly in the context of neurological disorders, there is notable therapeutic effectiveness being observed in cell therapy products based on mesenchymal stem/stromal cells (MSCs).

Global Placental Stem Cell Therapy for Neurological Disorders Market Drivers:

Increasing advancement in the scientific, technological, and medical fields has been fueling the growth of Global Placental Stem Cell Therapy.

Recent swift advancements in the genetic engineering of human pluripotent stem cells (hPSCs) have facilitated enhancements in techniques for targeted differentiation, cell monitoring, gene function assessment, and genetic rectification. The emergence of nucleases-based technologies, including ZFNs, TALENs, and CRISPR/Cas9, holds the potential to streamline and make changes in genetic alterations in hPSCs and their subsequent generations, owing to their elevated success rates and simplified design procedures.

Increasing funding for stem cell research has been contributing to enhancing the growth of the market.

There is a higher need for improved treatments for diseases like auto-immune conditions, neurological problems, and heart diseases. This has led to more money being spent on studying cells and putting together all the research done so far. One of the main reasons the market is getting bigger is because a lot of money is being invested in researching and developing these treatments. Also, since more people need strong treatments to help them with their illnesses, the market is growing even more. Because researchers and both public and private organizations are putting in more effort and money, there are new chances for the market to grow faster.

The rise in the prevalence of neurological disorders and other chronic illnesses is augmenting the market for Placental stem cell therapy.

A large portion of the global population faces ongoing health issues. One out of every three adults across the world deals with chronic conditions. These persistent diseases have significantly affected the well-being and daily life of numerous individuals. Ailments like cancer, musculoskeletal and neurological disorders, long-lasting injuries, heart and digestive problems, and cancer itself can lead to hospitalization, lasting incapacity, reduced quality of life, and even death. Mesenchymal stem cells can enter and become part of various organs. They are used to treat diseases related to the lungs, spinal cord, autoimmune system, liver, bones, and cartilage. They also help address damage in multiple organs. The use of stem cells in managing conditions linked to inflammation, the immune system, and the breakdown of tissues proves to be an effective approach.

Global Placental Stem Cell Therapy Restraints and Challenges:

The expansion of the cell treatment market has faced obstacles due to its high costs. As people seek out the latest options for therapies, cell treatments have become a popular choice. Despite the growing demand, these treatments remain quite expensive to undergo. Simple joint injections, for instance, could cost around $1,000, while more complex procedures might reach up to $100,000. Additionally, the strict regulatory environment adds to the challenges faced by the market.

Even though there has been rapid progress in pluripotent stem cell (PSC) research over the past three decades, these cells are not yet fully understood for therapeutic use. The foundational principles of generating, characterizing, and cultivating PSCs are widely recognized. While much of the risk and issues tied to the creation and cultivation of PSCs have been largely addressed through research, ethical concerns persist. The development of induced pluripotent stem cells (iPSCs) is helping to tackle these ethical concerns.

Global Placental Stem Cell Therapy for Neurological Disorders Market Opportunities:

The placental stem cell market is poised for significant growth, presenting a range of promising opportunities. Placental stem cells have shown remarkable versatility and efficacy in addressing neurological disorders. As research continues to uncover new therapeutic avenues, the market stands to benefit from the increasing demand for innovative and effective treatments. As public awareness and acceptance of regenerative medicine grow, the demand for alternative treatment options is on the rise. The placental stem cell market holds a wealth of opportunities driven by expanding clinical applications, technological advancements, collaborative efforts, and increasing patient demand. As research and innovation continue to pave the way, the market is poised to offer lucrative business opportunities in the coming years.

PLACENTAL STEM CELL THERAPY FOR NEUROLOGICAL DISORDERS MARKET REPORT COVERAGE:

Global Placental Stem Cell Therapy for Neurological Disorders Market Segmentation: By Type

• Allogeneic Placental Stem Cell Therapy

• Autologous Placental Stem Cell Therapy

In 2022, allogeneic placental stem cell therapy has dominated the segment within the market due to its unique capability to establish a new immune system in patients when donor cells successfully integrate into the recipient's body. This approach holds significant potential for treating both cancerous and non-cancerous conditions, encompassing neurological disorders, acute and chronic leukemia, Hodgkin's lymphoma, adrenoleukodystrophy, bone marrow failure syndromes, and more, through allogeneic stem cell transplants.

The escalating population of individuals dealing with cancer has contributed to the growing demand for treatments like Omidubicel, an advanced cell therapy designed for individuals with blood cancer. This demand is expected to fuel expansion within this specific segment. The segment's growth is also attributed to its cost-effectiveness and the expanding accessibility of stem cell banking services.

Moreover, the proactive shift of several cell therapy companies towards developing allogeneic cell therapy products adds to the momentum of this segment's growth. As these developments continue, the landscape of allogeneic stem cell therapy is set to witness remarkable expansion, solidifying its position as a pivotal player in the realm of medical treatments.

Autologous Placental Stem Cell Therapy is the largest growing market during the forecast period.

Global Placental Stem Cell Therapy for Neurological Disorders Market Segmentation: By End-User

• Hospitals & Specialty Clinics

• Clinics Research Organizations

• Research Institutes & Academics

The clinical research organizations segment holds a dominant position in the market, with the highest market share in 2022. This dominance can be attributed to the upsurge in research and development and the accessibility of funding dedicated to cell-focused investigations, driven by the urgent requirement for more advanced and effective treatments targeting autoimmune, cardiovascular, and neurological disorders. Furthermore, the escalating desire for biologics and the expanding scope of research aimed at unearthing novel acquisition approaches that have potential applications in developing personalized medicines collectively contribute to the robust expansion of the clinical research organizations sector. Hospitals and Specialty Clinics are the largest growing market and are expected to hold a substantial market share during the forecast period.

Global Placental Stem Cell Therapy for Neurological Disorders Market Segmentation: By Region

• North America

• Europe

• Asia-Pacific

• South America

• Middle East & Africa

In 2022, the North American region held the world’s 35% market share, making it the most dominant region in the segment. This can be attributed to the increasing allocation of research grants and both public and private investments dedicated to the advancement of safe and efficacious stem cell therapy products. Notably, the United States is a focal point, with a notable surge in clinical trials focused on placental stem cell applications, driving the overall growth trajectory in the region. Furthermore, the continuous evolution of placental stem cell therapy and the exceptional state of the healthcare sector synergistically contribute to the remarkable expansion of the market across North America.

Asia-Pacific region is the largest growing region and emerges as the foremost driver of growth on a global scale. Projections suggest that the Asia-Pacific stem cell therapy sector will experience substantial expansion over the upcoming decade. This projection is supported by the active participation of numerous public and private foundations, dedicated to providing financial backing and support for initiatives in stem cell-based research. The extensive landscape of the stem cell therapy industry encompasses a diverse array of drugs derived from stem cells, targeting an assortment of ailments such as cancer, tissue regeneration, injuries, and accidents.

COVID-19 Impact on the Global Placental Stem Cell Therapy for Neurological Disorders Market:

The outbreak prompted a series of challenges that affected both the demand and supply aspects of this specialized therapeutic area. Moreover, clinical trials, which are essential for advancing and validating new therapies, faced disruptions due to lockdowns, travel restrictions, and reduced access to medical facilities. However, amidst these challenges, the pandemic also shed light on the potential benefits of stem cell therapies, including those derived from placental sources. Research into the immunomodulatory and anti-inflammatory properties of placental stem cells gained attention in the context of treating COVID-19 complications. The overall impact of COVID-19 on the Placenta stem cell market was moderate and it is set to experience a huge comeback with an array of opportunities.

Latest trends/ Developments:

Industry participants are showing a strong inclination towards integrating advanced technologies and methodologies to maintain a consistent level of stem cell quality. This strategic approach aims to broaden the scope of clinical applications for placental stem cell therapies.

Within the placental stem cell therapy sector, enterprises are directing their attention toward achieving a dependable and high-quality cell production process. Notably, ReNeuron, a notable player engaged in developing therapeutics derived from stem cells specific to the retina, is intensifying its endeavors to harmonize scientific precision with a touch of artistry. This strategic approach aims to ensure unwavering uniformity in cell manufacturing, a critical aspect for effectively addressing conditions like retinitis pigmentosa.

The placental stem cell therapy market is witnessing a growing interest in utilizing allogeneic stem cell transplantation as a comprehensive approach to treating neurological disorders. The field of cell therapy for neurological conditions is rapidly progressing. Notably, during the evaluation of various cell types, each demonstrates its distinct benefits and limitations due to their specific molecular mechanisms. As a result, the idea of conducting combined transplantation of two or more types of cells has emerged as a promising concept.

There is a notable shift towards realizing potential therapeutic effects through the transplantation of a varied array of autologous or allogeneic stem/progenitor cells. This includes cell types such as embryonic and induced pluripotent stem cells, which have showcased encouraging outcomes in preclinical studies involving animal models of neurological ailments. As a consequence, these constructive research findings are currently evolving into viable revenue opportunities for companies engaged in this specific sector.

Key Players:

1. Mesoblast Ltd.

2. Pluristem Therapeutics

3. ReNeuron Group

4. AthersysInc.

5. Cordlife India

6. LifeCell International Pvt. Ltd

7. Cryo-Cell International Inc.

8. CBR Systems

9. Cellularity Inc.

10. Cynata

In December 2022, Celularity Inc., a clinical-stage biotech firm dedicated to the advancement of allogeneic cell therapies and biomaterial products sourced from the placenta, revealed its attainment of Halal Certification for its business models. This certification extends to its biomaterial products in the commercial stage, as well as its cellular therapeutic programs at both clinical and investigational stages.

In May 2022, ViaCyte, Inc. collaborated with SQZ Biotechnologies to jointly develop and bring to market microfluidic intracellular delivery technology for research-use-only (RUO) purposes. This partnership facilitates the exchange of innovative research in hematopoietic stem cell engineering between both entities involved in the market.